Estrogen plus progestin therapy and breast cancer in recently postmenopausal women

American Journal of Epidemiology

Volumn 167, Issue 10, 2008, Pages 1207-1216

  Prentice, Ross L ^a   Chlebowski, Rowan T ^b   Stefanick, Marcia L ^c   Manson, Joann E ^d   Pettinger, Mary ^a   Hendrix, Susan L ^e   Hubbell, F Allan ^f   Kooperberg, Charles ^a   Kuller, Lewis H ^g   Lane, Dorothy S ^h   McTiernan, Anne ^a   Jo O'Sullivan, Mary ⁱ   Rossouw, Jacques E ^j   Anderson, Garnet L ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^h STONY BROOK UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MIAMI   (United States)

^j NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

more..

Author keywords

Breast neoplasms; Clinical trials as topic; Cohort studies; Estrogens; Hormone replacement therapy; Postmenopause; Progestins

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE;

CANCER; COHORT ANALYSIS; COMPARATIVE STUDY; ESTROGENIC COMPOUND; HEALTH RISK; HORMONE; WOMENS HEALTH;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; POSTMENOPAUSE; TREATMENT DURATION; UNITED STATES; WOMEN'S HEALTH; AGED; BREAST TUMOR; CANCER INVASION; CHEMICALLY INDUCED DISORDER; ESTROGEN THERAPY; MIDDLE AGED; OBSERVATION; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK; TIME;

EQUIDAE;

AGED; BREAST NEOPLASMS; COHORT STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NEOPLASM INVASIVENESS; OBSERVATION; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TIME FACTORS;

EID: 43249111337     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwn044     Document Type: Article

References (29)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
2. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative randomized trial. JAMA 2003;289:3243-53.
3. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
4. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-59.
5. Colditz GA. Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin Cancer Res 2005;11(pt 2):909S-17S.
6. Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 2005;92:2049-58.
7. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103-15.
8. Hays J, Hunt JR, Hubbell FA, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol 2003;13(suppl):S18-77.
9. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19:61-109.
10. Langer RD, White E, Lewis CE, et al. The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 2003;13(suppl):S107-21.
11. Anderson GL, Linacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
12. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogen on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-57.
13. Curb D, McTiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication methods in the WHI. Ann Epidemiol 2003;13(suppl):S122-8.
14. Cox DR. Regression models and life tables (with discussion). J R Stat Soc (B) 1972;34:187-220.
15. Prentice RL, Langer RD, Stefanick ML, et al. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol 2006;163:589-99.
16. Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005;162:404-14.
17. Gail MH, Constantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-46.
18. Santen RJ, Lobenhofer EK, Afshari CA, et al. Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells. Breast Cancer Res Treat 2005;94:213-23.
19. Jeng MH, Shupnik MA, Bender TP, et al. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 1998;139:4164-74.
20. Santen RJ, Song RX, Zhang Z, et al. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer 2005;12(suppl);S61-73.
21. Greendale GA, Reboussin BA, Sloan S, et al. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-7.
22. McTiernan A, Martin CF, Peck JP, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst 2005;97:1366-76.
23. Van Dujnhoven FJB, Peeters PHM, Warren RML, et al. Postmenopausal hormone therapy and changes in mammographic density. J Clin Oncol 2007;25:1323-8.
24. Milanese TR, Hartman LC, Sellers TA, et al. Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst 2006;98:1600-7.
25. Chlebowski RT, Anderson GL, Pettinger M, et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med 2008;168:370-7.
26. Greendale GA, James MK, Espeland MA, et al. Can we measure prior postmenopausal estrogen/progestin use? The Postmenopausal Estrogen/Progestin Intervention Trial. The PEPI Investigators. Am J Epidemiol 1997;146:763-70.
27. Paganini-Hill A, Clark LJ. Comparison of patient recall of hormone therapy with physician records. Menopause 2007;14:230-4.
28. Hahn RA, Eaker E, Rolka H. Reliability of reported age at menopause. Am J Epidemiol 1997;146:771-5.
29. Tonkelaar I. Validity and reproducibility of self-reported age at menopause in women participating in the DOM-project. Maturitas 1997;27:117-23.